Previous 10 | Next 10 |
The company has a specific opportunity to be a vaccine supplier within Asia and to the world. Re-instated trials are proceeding after disappointment earlier in the year. As a well-capitalised company, there should be no shareholder risk dilution for a couple of years. Company ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2020, the race for the Covid-19 vaccine distorted investment inflows in the biotechnology sector. Back then, emerging biotech stocks tripled or more on hopes that they would come out with a vaccine. Buying interest in ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +123%. Lightning eMotors (NYSE:ZEV) +52%. 3D Systems (NYSE:DDD) +41%. MediaCo (NASDAQ:MDIA) +40%. Allied Healthcare Products (NASDAQ:AHPI) +27%. Exagen (NASDAQ:XGN) +26%. IMV (NASDAQ:IMV) +23%. Arcturus Therapeutics (NASDAQ:ARCT) +21%. Orphazyme A/S...
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2021 Earnings Conference Call August 09, 2021, 04:30 PM ET Company Participants Neda Safarzadeh - Head of Investor Relations, Public Relations and Marketing Joseph Payne - President and Chief Executive Officer Andy Sassine - Chief Financial Office...
ARCT-021, Arcturus’ single shot STARR™ mRNA COVID vaccine, to begin multinational placebo-controlled Phase 3 efficacy study funded and sponsored by a global entity ARCT-154, Arcturus’ STARR™ mRNA vaccine candidate targeting COVID variants of concern...
Do You Have These Top Health Care Stocks On Your Watchlist This Month? There have been mixed sentiments over the broader stock market over the past month. While many stocks are trading near record-high levels, there are also rising fears of the impact of the fast-spreading delta...
Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...
Gainers: Wilhelmina International (NASDAQ:WHLM) +90%. Arcturus Therapeutics Holdings (NASDAQ:ARCT) +29%. Translate Bio (NASDAQ:TBIO) +29%. Hollysys Automation (NASDAQ:HOLI) +26%. Lava Therapeutics B.V. (NASDAQ:LVTX) +24%. Flora Growth Corp. (NASDAQ:FLGC) +23%. Harmonic (NASDAQ:HLIT) +18%. Uni...
Shares of Arcturus Therapeutics (NASDAQ: ARCT) were soaring 34.7% higher as of 10:56 a.m. EDT on Tuesday. The big jump came after the company announced that Singapore regulators approved the advancement of two messenger RNA COVID-19 vaccine candidates into phase 1/2 clinical testing...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...